Johnson & Johnson (NYSE: JNJ) has secured United States Food and Drug Administration accelerated approval for Rybrevant Faspro, a subcutaneous formulation of amivantamab and hyaluronidase-lpuj, as a single-agent treatment for selected adults with recurrent or metastatic head and neck squamous cell carcinoma. Announced on 5 November 2026, the approval covers patients whose disease has progressed on or after platinum-based chemotherapy and an anti-PD-1 or anti-PD-L1 antibody, excluding HPV-associated oropharyngeal squamous cell carcinoma.
The decision is supported by the Phase 1b/2 OrigAMI-4 study, which reported a confirmed overall response rate of 42% among 102 previously treated patients, including complete responses in 15%. More than half of patients who responded maintained their response for at least six months, providing evidence of antitumour activity in a population with limited subsequent treatment options.
The approval marks the first authorised use of Rybrevant Faspro beyond non-small cell lung cancer and introduces dual epidermal growth factor receptor and MET targeting into a defined advanced head and neck cancer setting. However, accelerated approval is based on tumour response and response duration rather than a demonstrated survival advantage from a randomised comparison.
The next major clinical test will involve confirmatory evidence from the Phase 3 OrigAMI-5 programme, which is investigating an amivantamab-based combination in first-line recurrent or metastatic disease. Its findings will influence whether the benefits anticipated from dual EGFR and MET inhibition can be established through more mature comparative outcomes.
Which patients are eligible for Rybrevant Faspro under the new FDA head and neck cancer approval?
The FDA approval applies to adults with recurrent or metastatic head and neck squamous cell carcinoma whose cancer has progressed on or after both platinum-based chemotherapy and treatment with an anti-PD-1 or anti-PD-L1 antibody. This defines a previously treated population rather than all patients newly diagnosed with advanced head and neck cancer.
The label also contains an important exclusion. Rybrevant Faspro is not indicated for patients with HPV-associated oropharyngeal squamous cell carcinoma, a disease category identified through relevant HPV-associated testing, including p16 immunohistochemistry.
This distinction is clinically meaningful because head and neck squamous cell carcinoma encompasses tumours arising from different anatomical locations and with different biological characteristics. HPV-associated oropharyngeal cancers can differ from HPV-unassociated disease in their epidemiology, treatment response and prognosis.
The pivotal OrigAMI-4 efficacy cohort excluded patients with p16-positive oropharyngeal cancer. Consequently, the approval cannot be interpreted as evidence that Rybrevant Faspro is effective for that excluded population.
The authorised use is also limited to the subcutaneous formulation and the specified treatment setting. It does not authorise the medicine as first-line monotherapy for head and neck cancer or establish that every amivantamab-containing regimen has equivalent evidence in this disease.
The FDA granted the indication through its accelerated approval pathway after earlier granting Breakthrough Therapy designation in February 2026 and Priority Review designation in July. Those earlier regulatory decisions facilitated development and review but were not themselves marketing authorisations.
The November approval represents a completed regulatory decision, although continued approval may depend on subsequent verification of clinical benefit. That requirement distinguishes the current indication from an approval supported by completed confirmatory survival or other direct clinical outcome evidence.
How strong were the 42% response and 15% complete response findings in OrigAMI-4?
OrigAMI-4 is an ongoing, multicentre, open-label Phase 1b/2 trial evaluating subcutaneous amivantamab across different head and neck cancer treatment settings. The population supporting accelerated approval consisted of 102 adults with recurrent or metastatic disease who had previously received platinum-based chemotherapy and an immune checkpoint inhibitor.
Participants received weight-based Rybrevant Faspro as single-agent therapy, administered subcutaneously every three weeks until disease progression or unacceptable toxicity. The principal efficacy measure was overall response rate, determined through blinded independent central review using RECIST version 1.1 criteria.
The study demonstrated a confirmed overall response rate of 42%, with a 95% confidence interval ranging from 32% to 52%. Fifteen patients achieved complete responses, corresponding to 15% of the study population, while 28 experienced partial responses.
Complete response indicates the disappearance of measurable target disease under the applicable assessment criteria, but it does not necessarily establish permanent eradication of cancer. Patients require continued follow-up because recurrence or subsequent progression remains possible.
Among the 43 confirmed responders, 24 maintained a response for at least six months, representing 56% of those who responded. At the analysis cutoff, 63% of responders continued to have an ongoing response, and median duration of response had not been reached by blinded central review.
The peer-reviewed results were published in the Journal of Clinical Oncology in 2026, strengthening the evidence beyond the company’s regulatory announcement. Median follow-up was 11.8 months, providing useful but still relatively limited information about the duration of benefit in a serious malignancy.
The study also reported a median progression-free survival of 6.8 months and median overall survival of 12.5 months. These outcomes provide descriptive information about the treated population, but the absence of a randomised comparator prevents determining how much survival benefit is attributable to amivantamab.
The distinction is fundamental to evaluating accelerated approval. The observed tumour responses demonstrate clinically relevant antitumour activity, while the magnitude of any comparative survival benefit remains unestablished.
Why is dual EGFR and MET targeting a potentially important approach in head and neck cancer?
Rybrevant Faspro contains amivantamab, a bispecific antibody that binds epidermal growth factor receptor and MET. Both signalling pathways can contribute to cellular proliferation, survival and tumour progression in different cancers.
EGFR overexpression has long been recognised as a common biological feature of head and neck squamous cell carcinoma. Established treatment approaches have included EGFR-directed medicines such as cetuximab, although therapeutic response varies and disease progression remains common.
MET signalling provides an additional target associated with tumour biology and potential mechanisms of resistance. The rationale for amivantamab is that simultaneous targeting of EGFR and MET may interfere with more than one signalling pathway involved in tumour progression.
The antibody also possesses immune cell-directing activity, creating a mechanism that extends beyond conventional inhibition of individual growth factor receptors. This provides a biological basis for investigating the medicine in tumours where EGFR and MET activity may contribute to disease behaviour.
Johnson & Johnson has described the dual mechanism as a potential means of addressing treatment resistance and generating additional clinical responses. However, the underlying molecular rationale should not be confused with proof that dual targeting produces superior survival outcomes.
The OrigAMI-4 study did not randomise patients between amivantamab and a single-target treatment. It therefore cannot establish whether simultaneous EGFR and MET inhibition is clinically superior to EGFR inhibition alone.
The study also excluded patients with prior anti-EGFR treatment, an important consideration when assessing how the results apply to patients previously exposed to cetuximab. Treatment histories can influence response and the relevance of subsequent treatment options.
Further development could help clarify whether specific molecular characteristics predict responsiveness to amivantamab. However, the current approval does not establish a biomarker-selection requirement based on a particular EGFR or MET alteration.
How does the five-minute subcutaneous injection change the treatment delivery proposition?
Rybrevant Faspro combines amivantamab with recombinant human hyaluronidase, enabling subcutaneous administration instead of conventional intravenous delivery. The formulation incorporates Halozyme Therapeutics’ ENHANZE technology to facilitate delivery of the antibody through subcutaneous tissue.
Johnson & Johnson has highlighted an administration time of approximately five minutes. Compared with an intravenous infusion requiring a longer administration period, this may reduce the amount of time needed for the drug administration itself.
The distinction could be operationally relevant to oncology clinics managing substantial infusion capacity demands. Shorter administration may create opportunities to adjust treatment scheduling and reduce reliance on prolonged infusion-chair occupancy.
However, administration time is not equivalent to the total duration of a treatment visit. Patient assessment, preparation, monitoring and management of potential adverse reactions may still require additional clinical resources.
The medicine’s subcutaneous route does not eliminate the need for trained healthcare professionals or appropriate management of hypersensitivity and administration-related reactions. Operational benefits will depend on how the complete treatment pathway is organised within individual institutions.
The formulation may also influence patient convenience, particularly among individuals experiencing significant disease-related symptoms. Advanced head and neck cancer can affect swallowing, speech, nutrition and other daily activities, making the overall burden of treatment an important consideration.
Nevertheless, convenience should be assessed separately from antitumour efficacy. A shorter administration route cannot compensate for inadequate clinical benefit, and hospitals must evaluate the therapy’s total costs and resource requirements rather than injection time alone.
What safety risks emerged in the 102-patient OrigAMI-4 study?
The safety profile requires careful consideration because patients receiving Rybrevant Faspro may already have substantial disease-related complications and prior treatment exposure. The peer-reviewed OrigAMI-4 results reported that all 102 participants experienced at least one treatment-emergent adverse event.
Grade 3 or higher treatment-emergent adverse events occurred in 60% of patients, while serious adverse events were reported in 39%. Treatment-related adverse events led to discontinuation of amivantamab in 8% of participants.
The most common adverse reactions identified in the regulatory announcement included rash in 79% of patients, fatigue in 39%, nail toxicity in 35%, stomatitis in 32% and oedema in 28%. These events are relevant to treatment tolerability and may require additional clinical management.
Administration-related reactions were reported in 15% of participants in the published study and were classified as Grade 1 or Grade 2. Although these reactions were predominantly lower grade, clinicians must still be prepared to recognise and manage them.
The approved prescribing information includes warnings concerning hypersensitivity and administration-related reactions, interstitial lung disease or pneumonitis, dermatological adverse reactions, ocular toxicity and embryo-fetal toxicity.
Interstitial lung disease is a particularly important potential complication because it can be serious or fatal. Respiratory symptoms arising during treatment require appropriate clinical evaluation under the medicine’s prescribing information.
The presence of substantial adverse event rates does not independently establish that the medicine’s risks outweigh its benefits. Patients with advanced recurrent or metastatic cancer may have limited alternatives, and benefit-risk assessments must consider the severity of the disease and the available treatment options.
However, the safety data should not be reduced to a general statement that no new signals were observed. A complete evaluation must consider severe adverse events, treatment discontinuations, the duration of exposure and the extent to which complications can be managed in routine practice.
Why is the Phase 3 OrigAMI-5 trial essential after accelerated FDA approval?
The FDA’s accelerated approval pathway permits marketing of certain treatments for serious conditions based on surrogate or intermediate endpoints reasonably likely to predict clinical benefit. In oncology, tumour response and response duration can provide evidence supporting such decisions when the disease burden and unmet need justify an expedited approach.
The pathway nevertheless creates an important evidentiary requirement. The expected clinical benefit must be verified and described through appropriate subsequent research, and continued approval can depend on those findings.
For Rybrevant Faspro, Johnson & Johnson has identified the ongoing Phase 3 OrigAMI-5 trial as the confirmatory programme. The study is investigating subcutaneous amivantamab combined with carboplatin and pembrolizumab as a first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma.
This represents a different treatment setting from the approved single-agent indication. OrigAMI-4 evaluated previously treated patients, while OrigAMI-5 investigates an amivantamab-containing combination earlier in the treatment pathway.
The difference matters when interpreting the evidence. Outcomes observed with an investigational combination cannot simply be attributed to the single-agent medicine, and findings in first-line patients cannot automatically be applied to individuals whose cancer has progressed after several treatments.
The confirmatory trial will need to establish clinical benefit through its prespecified design and endpoints. Its eventual results may support the current accelerated approval and could also inform subsequent regulatory development, depending on the data and agency assessment.
The timeline for those outcomes will depend on enrolment, event accumulation, follow-up and the completion of the relevant analyses. The November approval announcement does not establish that confirmatory benefit has already been demonstrated.
Until those results become available, the current evidence supports the approved use based on response and durability while leaving comparative survival questions open.
How does the head and neck cancer approval expand Johnson & Johnson’s amivantamab franchise?
Amivantamab was initially developed and commercialised within Johnson & Johnson’s lung cancer portfolio. Its established mechanism of EGFR and MET inhibition underpins several approved non-small cell lung cancer indications, including treatment combinations addressing defined EGFR-mutated disease.
The head and neck cancer approval provides the first indication for Rybrevant Faspro beyond lung cancer, extending the molecule into another solid tumour category. This creates an additional commercial opportunity while building on development and manufacturing capabilities associated with an existing antibody programme.
The new market will nevertheless be narrower than the overall head and neck cancer population. Patients must meet the specific treatment-history requirements and cannot have HPV-associated oropharyngeal squamous cell carcinoma covered by the exclusion.
The medicine also competes within a treatment environment that includes established chemotherapy, immunotherapy and EGFR-directed options. Its position will depend on how oncologists interpret the response data, manage adverse events and integrate the therapy into existing treatment sequences.
Johnson & Johnson’s third-quarter 2026 results provide financial context for the wider franchise. The company reported quarterly sales of US$25.4 billion, representing 5.9% year-on-year growth, and increased its full-year financial guidance.
Combined worldwide revenue for Rybrevant and Lazcluze reached approximately US$320 million during the quarter, compared with US$198 million in the corresponding period of 2025. This represents growth of approximately 62%, although the reported figure combines two medicines and cannot be used to isolate Rybrevant Faspro revenue.
The new head and neck cancer indication was approved after the quarter ended and therefore did not contribute commercial revenue during that reporting period.
Its future revenue contribution will depend on patient eligibility, pricing, reimbursement, treatment duration and adoption within specialist oncology centres. Approval establishes market access under the authorised indication, but does not guarantee broad payer coverage or rapid prescribing uptake.
The regulatory review also took place through the FDA’s Project Orbis initiative, with participation from regulatory authorities in Brazil, Canada, Israel and Singapore. This provides an international review framework, although participation does not mean that each jurisdiction has granted marketing authorisation.
What will determine Rybrevant Faspro’s longer-term place in advanced head and neck cancer treatment?
The immediate significance of the approval is that clinicians have an additional authorised treatment option for a defined group of adults with recurrent or metastatic disease after platinum chemotherapy and immune checkpoint inhibition.
The 42% response rate and 15% complete response rate provide meaningful evidence of antitumour activity. Yet the single-arm trial cannot establish superiority over available alternatives, and the median follow-up remains relatively limited for evaluating longer-term outcomes.
Clinical adoption will depend on the complete benefit-risk profile, including the management of dermatological events, administration-related reactions and serious complications. The subcutaneous formulation may provide operational advantages, but those benefits must be assessed within the wider clinical treatment pathway.
For Johnson & Johnson, the approval expands a growing oncology franchise while creating an additional obligation to generate confirmatory evidence. The company’s ability to translate the regulatory milestone into sustained commercial value will depend on clinical confidence, reimbursement access and the eventual results of its Phase 3 programme.
The next decisive development will be evidence capable of verifying clinical benefit beyond tumour shrinkage. OrigAMI-5 will be closely watched because it addresses whether an amivantamab-based strategy can produce meaningful comparative outcomes in a different treatment setting.
Rybrevant Faspro’s accelerated approval represents a significant expansion of EGFR and MET dual targeting into head and neck cancer. Its response data establish a credible basis for use in the precisely defined approved population, while the safety profile and remaining survival uncertainties require careful consideration. Demonstrating durable clinical benefit through confirmatory research will determine how securely the medicine establishes itself within advanced head and neck oncology.
